High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
about
Chronic myeloid leukemia: reminiscences and dreamsEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaImatinib in chronic myeloid leukemia: an overviewSecondary mutations as mediators of resistance to targeted therapy in leukemiaPhase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizatiResults of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.Measuring symptoms as a critical component of drug development and evaluation in hematological diseasesImatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaTargeted treatment of chronic myeloid leukemia: role of imatinib.Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire.Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based reviewTyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.Characterization of chronic myeloid leukemia stem cells.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaCritical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatinLong-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinibCurrent event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.The choice of first-line chronic myelogenous leukemia treatment.Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.The development and application of imatinib.
P2860
Q26748769-0A333B7C-E586-4CB1-A97E-A60C54A94E1DQ26749324-9F6D60AE-6729-4BB5-A8B7-037E90EB5796Q26865086-8AE6BD4A-7EAC-4740-BCE1-5E0456D16590Q28087213-C5D71391-E308-4994-86F3-D1F39D4A7035Q30357011-CFE1E725-288B-407A-94FA-7A6AD22F7CDFQ33387517-C6EBA505-51FB-4283-AE50-1D84F65B51E2Q33387519-9E18FA1F-F810-4A51-8538-1AA673912CDFQ33390293-9D41AF59-B542-46BB-8111-B653D958E672Q33396265-51ADD693-D11A-4A8C-B70E-E797DACEF300Q33557847-BA7D0759-0406-4255-BE80-ECB7B18EDC5BQ33561232-5AF34699-23C3-4BAE-97B3-7B79DE80B084Q33597519-E066F966-0DF7-450C-B87F-1C6C9EB693E2Q33705743-54F36B2F-A49D-468E-8A20-E23D12BE211DQ33844109-7D9CC147-702D-4368-9FDC-F449AABC93F4Q33886162-FEB7BEBD-1F14-43F0-B04C-53E3D6FB0AC0Q33886167-5BB4B30F-2DB3-4246-B276-8C532F065854Q33915973-20381C3B-351A-4253-A168-09C4ABEF86B6Q33915990-BCF089C3-B47B-4C93-8C04-CD25A692EADDQ33926222-A2516B0F-832D-4DC1-805E-EE38A6055247Q34022596-48F77207-CEF2-4048-8738-851C22965C53Q34123610-2C8C1F4C-D5E4-432A-B011-22029E191D7FQ34130343-D6987378-1DE4-41EB-8892-8100A65BA84BQ34272962-A81D6947-E4C2-4DB6-95ED-F4A68576DE44Q34443523-DA8ED9DB-6747-4293-B2C7-2AAA55441652Q34443802-13A30DCD-132A-48E1-86FB-4296D9477DCBQ34522789-8BA601B4-B971-489B-9777-75734C08850EQ34894883-81F09893-285F-43C3-832D-881C104B7E0EQ35034528-31E9B6E2-5976-4C82-9BB9-52746E4A4648Q35073857-4F29F1EF-1164-4AAC-AEDB-712DF3DA9E73Q35083184-0FA4F58E-C78C-44D2-AD7C-24DDAF913A46Q35221071-5073A754-28B5-4D02-9E05-3B3771BE2703Q35300745-51BA7BC5-A454-488E-A891-051F7E556FC6Q35790163-6773FD95-798E-43AD-8599-AE6682EC7811Q35816396-81031474-9D70-48A3-9200-EF6AB890700BQ35847727-25BD82A9-460D-4044-BD65-A0D0A29ABB35Q35876347-F8732659-736B-404B-8AEE-6DC3E32E1223Q35930616-AC024291-693B-48C4-9D90-997D17FCCCAEQ35949910-1A7759D6-D9E5-41DD-AA6E-1E831891DF8DQ36006408-01962504-50A4-4E41-8AD9-8A8D20A07E44Q36081983-9D0F7069-164F-4BD5-97F4-07D68E327EE5
P2860
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
High-dose imatinib mesylate th ...... hase chronic myeloid leukemia.
@en
High-dose imatinib mesylate th ...... hase chronic myeloid leukemia.
@nl
type
label
High-dose imatinib mesylate th ...... hase chronic myeloid leukemia.
@en
High-dose imatinib mesylate th ...... hase chronic myeloid leukemia.
@nl
prefLabel
High-dose imatinib mesylate th ...... hase chronic myeloid leukemia.
@en
High-dose imatinib mesylate th ...... hase chronic myeloid leukemia.
@nl
P2093
P50
P1433
P1476
High-dose imatinib mesylate th ...... hase chronic myeloid leukemia.
@en
P2093
Deborah Thomas
Jianqin Shan
Laurie Letvak
Moshe Talpaz
P304
P356
10.1182/BLOOD-2003-11-3800
P407
P50
P577
2003-12-24T00:00:00Z